• Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=28823557).
  

PubMed=28823557; DOI=10.1016/j.cell.2017.07.016; PMCID=PMC5587159
Qin E.Y., Cooper D.D., Abbott K.L., Lennon J., Nagaraja S., Mackay A., Jones C., Vogel H., Jackson P.K., Monje M.
Neural precursor-derived pleiotrophin mediates subventricular zone invasion by glioma.
Cell 170:845-859.e19(2017)

PubMed=31439867; DOI=10.1038/s41467-019-11732-6; PMCID=PMC6706443
Fons N.R., Sundaram R.K., Breuer G.A., Peng S., McLean R.L., Kalathil A.N., Schmidt M.S., Carvalho D.M., Mackay A., Jones C., Carcaboso A.M., Nazarian J., Berens M.E., Brenner C., Bindra R.S.
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Nat. Commun. 10:3790.1-3790.10(2019)

PubMed=33319914; DOI=10.1093/gigascience/giaa136; PMCID=PMC7736793
Sanders L.M., Cheney A., Seninge L., van den Bout A., Chen M., Beale H.C., Kephart E.T., Pfeil J., Learned K., Lyle A.G., Bjork I., Haussler D., Salama S.R., Vaske O.M.
Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma.
GigaScience 9:giaa136.1-giaa136.14(2020)

PubMed=34215733; DOI=10.1038/s41467-021-24168-8; PMCID=PMC8253809
He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N., Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J., Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J., Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P., Boop F., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M., Freeman B.B. 3rd, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z., Wu G., Chiang J.C.-H., Tinkle C.L., Shelat A.A., Baker S.J.
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma.
Nat. Commun. 12:4089.1-4089.17(2021)